Intervention Review

You have free access to this content

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

  1. Theresa A Lawrie1,*,
  2. Roy Rabbie2,
  3. Clemens Thoma3,
  4. Jo Morrison4

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 21 OCT 2013

Assessed as up-to-date: 14 AUG 2013

DOI: 10.1002/14651858.CD010482.pub2


How to Cite

Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010482. DOI: 10.1002/14651858.CD010482.pub2.

Author Information

  1. 1

    Royal United Hospital, Cochrane Gynaecological Cancer Group, Bath, UK

  2. 2

    Epsom and St Helier University Hospitals NHS Trust, Department of Respiratory Medicine, London, UK

  3. 3

    University of Oxford, Nuffield Department of Obstetrics & Gynaecology, Oxford, UK

  4. 4

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Theresa A Lawrie, Cochrane Gynaecological Cancer Group, Royal United Hospital, Education Centre, Bath, BA13NG, UK. tess@lawrie.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 OCT 2013

SEARCH

  1. You have free access to this content

    Current Version

    Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

    Theresa A Lawrie, Roy Rabbie, Clemens Thoma and Jo Morrison

    Article first published online: 21 OCT 2013 | DOI: 10.1002/14651858.CD010482.pub2

Previous versions of this article and their online publication dates

  1. You have free access to this content

    Version 1

    Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

    Theresa A Lawrie, Roy Rabbie, Clemens Thoma and Jo Morrison

    Article first published online: 30 APR 2013 | DOI: 10.1002/14651858.CD010482